When the Danish Medicines Council has determined the added clinical value of a new pharmaceutical, Amgros will negotiate with the applicant. The purpose of the negotiations is to agree on a price level that gives a reasonable match between the added clinical value of the pharmaceutical and its additional costs in relation to a comparable standard treatment.
Amgros bases the negotiation on two parameters. Firstly the assessment by the Danish Medicines Council of the added clinical value, and secondly our own assessment of the additional costs of the pharmaceutical.
After the negotiation with the applicant, Amgros will draw up a report to the Danish Medicines Council. This contains the result of the negotiation, the report on added clinical value, as well as an assessment of the additional costs of the pharmaceutical.
After this, the Danish Medicines Council decides finally whether it will recommend the pharmaceutical as a standard treatment at public hospitals.
Negotiations can begin when the final added clinical value of the drug has been published. This is usually eight weeks after the application. The negotiations themselves usually take 14 days. This includes time for administration as well as two or three negotiation meetings.
Amgros will enter into an agreement with the applicant, irrespective of whether the pharmaceutical is recommended by the Danish Medicines Council as a standard treatment at public hospitals.
Amgros has two teams who negotiate prices of new pharmaceuticals. Each team consists of a negotiator and a health economist. We select a permanent contact person for the negotiation process for each pharmaceutical.
Price negotiations and effective competition
Amgros manages procurement of almost all the medicine used in Danish public hospitals. It is our task to organise tendering procedures for pharmaceuticals so that we cover hospital needsREAD MORE
Is there is a reasonable relationship between the added clinical value from a new pharmaceutical compared with the existing treatment, and the costs this entails?READ MORE
If a new drug is to be considered as a standard treatment at Danish public hospitals, the Danish Medicines Council has to assess it first.READ MORE
Chief operating officer
My job is to ensure a uniform approach to treatment in the regions, possibilities to receive the newest treatments, and the most cost-effective health solutions.
Lasse Lund Gundtoft
I work as a negotiator for new pharmaceuticals and I coordinate Amgros' activities in relation to the Danish Medicines Council.